

**Bill Summary**  
1<sup>st</sup> Session of the 59<sup>th</sup> Legislature

<b>Bill No.:</b>	<b>SB 145</b>
<b>Version:</b>	<b>INT</b>
<b>Request No.:</b>	<b>1218</b>
<b>Author:</b>	<b>Sen. Hicks</b>
<b>Date:</b>	<b>01/04/2023</b>

**Bill Analysis**

SB 145 prohibits insurers from modifying an insured's coverage of a prescription drug if drug had been previously preauthorized for coverage, the insured already received the drug, and a practitioner continues to prescribe the drug. If the Food and Drug Administration (FDA) has issued a statement calling into question the clinical safety of the drug or if the FDA has been notified of a manufacturing discontinuance or potential discontinuance of the drug, the measure does not prohibit modification of coverage. Any insurer that violates the provisions of this measure shall be subject to a civil penalty in an amount determined by the Insurance Commissioner.

Prepared by: Kalen Taylor